4584-68-3

Usage

InChI:InChI=1/C7H5BrO2/c8-5-3-1-2-4-6(9)7(5)10/h1-4H,(H,9,10)

Upstream product

• 533-75-5 2-hydroxy-2,4,6-cycloheptatrien-1-one 
• 721-39-1 7-Brom-2-phenoxy-tropon 
• 3008-39-7 cycloheptane-1,2-dione 

Downstream Products

• 3054-77-1 3-bromo-2-methoxytropone 
• 1728-86-5 2-bromo-7-methoxytropone 
• 65425-62-9 3-methoxy-tropolone 
• 721-41-5 3-phenoxy-tropolone 
• 4636-41-3 3,7-dibromotropolone 
• 363-67-7 3,5,7-tribromotropolone 
• 412313-55-4 (+/-)-3,5,7-tribromo-cyclohepta-3,5-diene-1,2-dione 
• 34777-04-3 3-Hydroxytropolone 
• 98437-35-5 7-Brom-2-methyl-tropon 
• 33695-99-7 3,7-dibromo-2-methoxy-cycloheptatrienone 
• 76941-25-8 RuCl₂(C₇H₄BrO₂)(P(C₆H₅)3)2 
• 76941-27-0 RuBr₂(C₇H₄BrO₂)(P(C₆H₅)3)2 
• 76941-24-7 RuCl₂(C₇H₄BrO₂)(As(C₆H₅)3)2 
• 76941-26-9 RuBr₂(C₇H₄BrO₂)(As(C₆H₅)3)2 

Relevant academic research and scientific papers

Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: Identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication

We synthesized new tropolone derivatives substituted with cyclic amines: piperidine, piperazine or pyrrolidine. The most active anti-helicase compound (IC50= 3.4 μM), 3,5,7-tri[(4′-methylpiperazin-1′-yl) methyl]tropolone (2), inhibited RNA replication by 50% at 46.9 μM (EC 50) and exhibited the lowest cytotoxicity (CC50) >1 mM resulting in a selectivity index (SI = CC50/EC50) >21. The most efficient replication inhibitor, 3,5,7-tri[(4′-methylpiperidin- 1′-yl)methyl]tropolone (6), inhibited RNA replication with an EC 50 of 32.0 μM and a SI value of 17.4, whereas 3,5,7-tri[(3′- methylpiperidin-1′-yl)methyl]tropolone (7) exhibited a slightly lower activity with an EC50 of 35.6 μM and a SI of 9.8.

TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS

Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.

TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS

Disclosed are a series of compounds or their tautomers having a general structure represented by Formula (la), (lb), (Ila), (lIb), or (lIc) and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula (la), (lb), (Ila), (lIb), or (lIc) compounds or tautomers.

HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF

Disclosed are analogues of hinokitiol, methods for preparing them, and pharmaceutical compositions thereof. Also disclosed are methods for their use in treating iron-related diseases.

Anti-mycoplasma agent

An anti-mycoplasma agent comprising tropolone, its derivatives, represented by the formula: STR1 (wherein R1 is hydroxy, aliphatic acyloxy, arylacyloxy, arysulfonyloxy, carboxyalkyloxy or its ester, benzoylalkyloxy, alkenyloxy, 1,3-dihydro-3-oxo-1-isobenzofuranyloxy, (2-oxo-5-methyl-1,3-dioxol-4-yl)methyloxy or thiocyanato and R2 is hydrogen, halogen, hydroxy, alkyl or alkoxy) and their salts as an active ingredient, which has potent activity especially against tylosin-resistant mycoplasma both in vitro and in vivo and is effectively used in treating the diseases caused thereby.

4,9-Dihydro-4,9-dioxo-1H-cyclohepta[b]pyridine derivatives

Aldose reductase inhibitors of the formula STR1 in which R1 is COOH and R2 is hydrogen, 8-halo or 6-hydroxy, or R1 is CON(R3)-CH2 COOH wherein R3 is lower alkyl and R2 is hydrogen or 8-halo are useful for treating diabetic complications.